Cargando...
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
Immune checkpoint blockade therapy by targeting the programmed death protein 1/programmed death ligand 1 (PD-L1) axis using antibodies has yielded promising clinical responses in patients with non-small cell lung cancer (NSCLC). However, owing to the dynamic expression of PD-L1, degree of mutational...
Guardado en:
| Publicado en: | Clin Transl Med |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer Berlin Heidelberg
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5250626/ https://ncbi.nlm.nih.gov/pubmed/28108884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-017-0136-7 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|